- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Events
Page 77
Neuralink connects to GV to raise $205m
GV was among the participants in a series C round that boosted the neurological communication technology developer's total funding to more than $360m.
Aug 2, 2021Isar Aerospace increases scope of series B
Porsche was among the investors that supplied $75m to take the satellite launch vehicle developer's latest round to over $165m.
Aug 2, 2021Algolia inputs $150m at a $2.25bn valuation
Salesforce and Twilio backed the API platform developer in a series D round led by Lone Pine Capital, bringing its overall funding to $315m.
Aug 2, 2021Investors decode 1Password’s $100m series B
The Slack Fund-backed password management technology developer has raised a series B round that valued it at $2bn post-money.
Aug 2, 2021Investors get into Grover’s $100m series B round
The Assurant and Samsung-backed consumer device rental service has secured $29m in a series B extension provided by unnamed backers.
Aug 2, 2021Bota Bio sails to series B funding
The biological ingredient technology developer, which counts BASF Venture Capital and Baidu Ventures as investors, raised more than $100m.
Aug 2, 2021Deep Genomics jumps into $180m series C
University of Toronto-linked Deep Genomics has picked up $180m in its series C round led by SoftBank Vision Fund 2.
Jul 30, 2021Rakuten Medical racks up $166m
Rakuten and SBI have returned to chip into the precision immunotherapy developer’s series D round, which was led by General Catalyst.
Jul 30, 2021Figure fits $200m into series D round
Mitsubishi UFJ Financial Group-backed lending marketplace operator Figure has collected $200m in series D financing from investors including Blockchain.com.
Jul 30, 2021Deep Genomics taps SoftBank in $180m round
SoftBank and Alexandria Real Estate Equities helped the Bloomberg-backed genetic medicine developer raise series C funding to further expand its pipeline of RNA therapies.
Jul 30, 2021About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


